About: Pemigatinib

Facets (new session)
Description
Metadata
Settings
- Rule:
- Inverse Functional Properties:
- "Same As":

About: Pemigatinib Goto Sponge NotDistinct Permalink

An Entity of Type : dbo:Drug, within Data Space : dbpedia.demo.openlinksw.com associated with source document(s)
QRcode icon

http://dbpedia.demo.openlinksw.com/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FPemigatinib&invfp=IFP_OFF&sas=SAME_AS_OFF

Pemigatinib, sold under the brand name Pemazyre, is an anti-cancer medication used for the treatment of bile duct cancer (cholangiocarcinoma). Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading.

Attributes	Values
rdf:type	Thing dul:ChemicalObject chemical substance Drug drug
rdfs:label	ペミガチニブ (ja) Pemigatinib (en)
rdfs:comment	ペミガチニブ（Pemigatinib）は、に分類される胆管癌治療薬である。タンパク質キナーゼとして知られる酵素、特に癌細胞の表面に存在し増殖や転移に関与する線維芽細胞増殖因子受容体（FGFR）の一部を構成するチロシンキナーゼの阻害によって作用する。 FDA承認の臨床検査で検出された（FGFR2）の融合またはその他の再配列を有する、前治療歴のある切除不能な局所進行性または転移性胆管癌の成人患者を対象とする。 (ja) Pemigatinib, sold under the brand name Pemazyre, is an anti-cancer medication used for the treatment of bile duct cancer (cholangiocarcinoma). Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading. (en)
foaf:depiction
dcterms:subject	Orphan drugs Breakthrough therapy Receptor tyrosine kinase inhibitors
Wikipage page ID	63691273 (xsd:integer)
Wikipage revision ID	1115585615 (xsd:integer)
Link from a Wikipage to another Wikipage	Priority review Indication (medicine) International nonproprietary name Alopecia Stomatitis Oral administration Orphan drug Protein kinase inhibitors Protein kinases Committee for Medicinal Products for Human Use Fatigue Orphan drugs Dysgeusia European Medicines Agency Food and Drug Administration Foundation Medicine Breakthrough therapy Hyperphosphatemia Hypophosphatemia Breakthrough therapy Receptor tyrosine kinase inhibitors Bile duct cancer Anti-cancer medication
Link from a Wikipage to an external page	https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pemigatinib https://druginfo.nlm.nih.gov/drugportal/name/pemigatinib
sameAs	Pemigatinib Pemigatinib Pemigatinib Pemigatinib
dbp:wikiPageUsesTemplate	dbt:Cite_journal dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Use_American_English dbt:Use_dmy_dates dbt:Drugs.com dbt:Growth_factor_receptor_modulators dbt:ClinicalTrialsGov dbt:Targeted_cancer_therapeutic_agents
thumbnail	wiki-commons:Special:FilePath/Pemigatinib.svg?width=300
ATC suffix	EN02 (en)
ATC prefix	L01 (en)
c	24 (xsd:integer)
CAS number	1513857 (xsd:integer)
ChEMBL	4297522 (xsd:integer)
ChemSpiderID	68007304 (xsd:integer)
DrugBank	DB15102 (en)
F	2 (xsd:integer)
H	27 (xsd:integer)
IUPAC name	180.0 (second)
KEGG	D11417 (en)
legal US	Rx-only (en)
MedlinePlus	a620028 (en)
n	5 (xsd:integer)
O	4 (xsd:integer)
PubChem	86705695 (xsd:integer)
routes of administration	Oral administration
SMILES	CCN1C2=C3C=CCN5CCOCC5 (en)
StdInChI	1 (xsd:integer)
StdInChIKey	HCDMJFOHIXMBOV-UHFFFAOYSA-N (en)
synonyms	INCB054828 (en)
tradename	Pemazyre (en)
UNII	Y6BX7BL23K (en)
has abstract	Pemigatinib, sold under the brand name Pemazyre, is an anti-cancer medication used for the treatment of bile duct cancer (cholangiocarcinoma). Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading. Pemigatinib belongs to a group of medicines called protein kinase inhibitors. It works by blocking enzymes known as protein kinases, particularly those that are part of receptors (targets) called fibroblast growth factor receptors (FGFRs). FGFRs are found on the surface of cancer cells and are involved in the growth and spread of the cancer cells. By blocking the tyrosine kinases in FGFRs, pemigatinib is expected to reduce the growth and spread of the cancer. The most common adverse reactions are hyperphosphatemia and hypophosphatemia (electrolyte disorders), alopecia (spot baldness), diarrhea, nail toxicity, fatigue, dysgeusia (taste distortion), nausea, constipation, stomatitis (sore or inflammation inside the mouth), dry eye, dry mouth, decreased appetite, vomiting, joint pain, abdominal pain, back pain and dry skin. Ocular (eye) toxicity is also a risk of pemigatinib. Additional common adverse reactions include rash, anemia, epistaxis, serous retinal detachment, extremity pain, dyspepsia, blurred vision, peripheral edema, and dizziness. (en) ペミガチニブ（Pemigatinib）は、に分類される胆管癌治療薬である。タンパク質キナーゼとして知られる酵素、特に癌細胞の表面に存在し増殖や転移に関与する線維芽細胞増殖因子受容体（FGFR）の一部を構成するチロシンキナーゼの阻害によって作用する。 FDA承認の臨床検査で検出された（FGFR2）の融合またはその他の再配列を有する、前治療歴のある切除不能な局所進行性または転移性胆管癌の成人患者を対象とする。 (ja)
DailyMedID	Pemigatinib (en)
legal AU	S4 (en)
legal CA	Rx-only (en)
legal EU	Rx-only (en)
licence EU	yes (en)
pregnancy AU	D (en)
prov:wasDerivedFrom	wikipedia-en:Pemigatinib?oldid=1115585615&ns=0
page length (characters) of wiki page	18694 (xsd:nonNegativeInteger)
alternative name	Pemazyre (en)
CAS number	1513857-77-6
ChEMBL	4297522
DrugBank	DB15102
FDA UNII code	Y6BX7BL23K
KEGG	D11417
MedlinePlus	a620028
PubChem	86705695
foaf:isPrimaryTopicOf	wikipedia-en:Pemigatinib
is Link from a Wikipage to another Wikipage of	List of drugs granted breakthrough therapy designation Pemazyre

Faceted Search & Find service v1.17_git139 as of Feb 29 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 08.03.3330 as of Mar 19 2024, on Linux (x86_64-generic-linux-glibc212), Single-Server Edition (378 GB total memory, 59 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software